But there is substantial room for improvement: for example, responses to immune checkpoint agents relate (imperfectly) to expression levels of Programmed Cell Death Ligand 1 (PD-L1) in tumour cells or infiltrating immune cells in several types of cancer. This evidence concerns the gene CD274 and neoplasm.